Award

PARIS Trial Clinical Trials EDC system: A phase 2 study of PD-1 inhibition in Rheumatoid Arthritis, Ulcerative Colitis and Sjogrens syndrome

UNIVERSITY OF BIRMINGHAM

This public procurement record has 1 release in its history.

Award

09 Dec 2021 at 14:33

Summary of the contracting process

The University of Birmingham is seeking a supplier for the PARIS Trial Clinical Trials EDC system, specifically for a phase 2 study involving PD-1 inhibition in conditions such as Rheumatoid Arthritis, Ulcerative Colitis, and Sjögren's syndrome. This procurement falls under the goods category in the electronic data management (EDM) industry, with a contract value of £500,000. The procurement method used is limited, meaning it was negotiated without the publication of a contract notice. The procurement process is currently in the award stage, following the signing of the contract on 9th December 2021, with the system required to be operational by January 2022.

This tender presents significant opportunities for businesses involved in clinical data management and electronic data capture. Companies with experience in trial database systems, particularly those familiar with regulatory compliance across different regions, would be positioned well to compete. Given the specific requirements of the PARIS trial, businesses that can demonstrate expertise in managing clinical trials, suitable technical capabilities, and a clear understanding of the necessary regulations would likely find growth opportunities within this procurement process.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

PARIS Trial Clinical Trials EDC system: A phase 2 study of PD-1 inhibition in Rheumatoid Arthritis, Ulcerative Colitis and Sjogrens syndrome

Notice Description

The PARIS trial (Sponsored by the University of Birmingham) is an Investigator Initiated Trial which is funded by an industry collaborator. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by January 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.

Lot Information

Lot 1

The PARIS trial (Sponsored by the University of Birmingham) is an Investigator Initiated Trial which is funded by an industry collaborator. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by January 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.

Procurement Information

The preferred vendor for creating an EDC system for this trial is Medidata (Rave). Medidata meets the criteria outlined below that are essential for delivering the clinical trial. The company has a track record of delivering clinical trials to registration standard with other academic organisations and industry partners running clinical trials of this nature and was independently recommended to the University of Birmingham. Additionally, Medidata is in the process of undergoing a detailed audit of their systems with the University of Birmingham. This is an essential requirement to perform prior to the set-up of an electronic clinical trial database when required for registration standard trials. Critically, Medidata have successfully passed inspections by regulatory health authorities. Regular transfers of data to the industry collaborator will be required and therefore we require the same EDC platform to be used for ease of transfer. Medidata have confirmed their ability to deliver the clinical trial database in January 2022, within the budget and using Case Report Form (CRF) libraries held by the industry collaborator. The following are detailed reasons for the selection of Medidata as a vendor to provide an EDC system PARIS: * Experience in relevant disease group (Rheumatoid Arthritis, Ulcerative Colitis, Sjogren's Syndrome) * Access to CRF library for the diseases listed above * Access to industry partner CRF libraries * The same EDC system as the funder (industry collaborator) to enable ease of data transfer * Able to deliver a live clinical trial database for the study by January 2022 * Successfully passed a regulatory inspection and undergoing an audit by the University of Birmingham * Able to demonstrate compliance with regulations across all global regions * Able to implement major trial protocol amendments (new treatment arms) without requiring temporarily closures or existing live aspects of the database * Fall under a maximum budget of PS500,000 for the whole clinical trial database

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02ff58
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/030689-2021
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Limited
Procurement Method Details
Negotiated without publication of a contract notice
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

48 - Software package and information systems


CPV Codes

48613000 - Electronic data management (EDM)

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£500,000 £500K-£1M

Notice Dates

Publication Date
9 Dec 20214 years ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
9 Dec 20214 years ago
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Not Specified
Awards Status
Active
Contracts Status
Active

Contracting Authority (Buyer)

Main Buyer
UNIVERSITY OF BIRMINGHAM
Contact Name
Susanna Ting
Contact Email
s.y.ting@bham.ac.uk
Contact Phone
Not specified

Buyer Location

Locality
BIRMINGHAM
Postcode
B15 2TT
Post Town
Birmingham
Country
England

Major Region (ITL 1)
TLG West Midlands (England)
Basic Region (ITL 2)
TLG3 West Midlands
Small Region (ITL 3)
TLG31 Birmingham
Delivery Location
TLG31 Birmingham

Local Authority
Birmingham
Electoral Ward
Edgbaston
Westminster Constituency
Birmingham Edgbaston

Supplier Information

Number of Suppliers
1
Supplier Name

MEDIDATA SOLUTIONS INTERNATIONAL

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-02ff58-2021-12-09T14:33:36Z",
    "date": "2021-12-09T14:33:36Z",
    "ocid": "ocds-h6vhtk-02ff58",
    "initiationType": "tender",
    "tender": {
        "id": "SC9830/21",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "PARIS Trial Clinical Trials EDC system: A phase 2 study of PD-1 inhibition in Rheumatoid Arthritis, Ulcerative Colitis and Sjogrens syndrome",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "48613000",
            "description": "Electronic data management (EDM)"
        },
        "mainProcurementCategory": "goods",
        "description": "The PARIS trial (Sponsored by the University of Birmingham) is an Investigator Initiated Trial which is funded by an industry collaborator. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by January 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.",
        "lots": [
            {
                "id": "1",
                "description": "The PARIS trial (Sponsored by the University of Birmingham) is an Investigator Initiated Trial which is funded by an industry collaborator. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by January 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.",
                "hasOptions": false
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKG31"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Negotiated without publication of a contract notice",
        "coveredBy": [
            "GPA"
        ],
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_TECHNICAL",
                "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
            }
        ],
        "procurementMethodRationale": "The preferred vendor for creating an EDC system for this trial is Medidata (Rave). Medidata meets the criteria outlined below that are essential for delivering the clinical trial. The company has a track record of delivering clinical trials to registration standard with other academic organisations and industry partners running clinical trials of this nature and was independently recommended to the University of Birmingham. Additionally, Medidata is in the process of undergoing a detailed audit of their systems with the University of Birmingham. This is an essential requirement to perform prior to the set-up of an electronic clinical trial database when required for registration standard trials. Critically, Medidata have successfully passed inspections by regulatory health authorities. Regular transfers of data to the industry collaborator will be required and therefore we require the same EDC platform to be used for ease of transfer. Medidata have confirmed their ability to deliver the clinical trial database in January 2022, within the budget and using Case Report Form (CRF) libraries held by the industry collaborator. The following are detailed reasons for the selection of Medidata as a vendor to provide an EDC system PARIS: * Experience in relevant disease group (Rheumatoid Arthritis, Ulcerative Colitis, Sjogren's Syndrome) * Access to CRF library for the diseases listed above * Access to industry partner CRF libraries * The same EDC system as the funder (industry collaborator) to enable ease of data transfer * Able to deliver a live clinical trial database for the study by January 2022 * Successfully passed a regulatory inspection and undergoing an audit by the University of Birmingham * Able to demonstrate compliance with regulations across all global regions * Able to implement major trial protocol amendments (new treatment arms) without requiring temporarily closures or existing live aspects of the database * Fall under a maximum budget of PS500,000 for the whole clinical trial database"
    },
    "awards": [
        {
            "id": "030689-2021-SC9830/21-1",
            "relatedLots": [
                "1"
            ],
            "title": "PARIS Trial Clinical Trials EDC system: A phase 2 study of PD-1 inhibition in Rheumatoid Arthritis, Ulcerative Colitis and Sjogrens syndrome",
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-37276",
                    "name": "Medidata Solutions International Limited"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-31013",
            "name": "UNIVERSITY OF BIRMINGHAM",
            "identifier": {
                "legalName": "UNIVERSITY OF BIRMINGHAM"
            },
            "address": {
                "streetAddress": "University of Birmingham",
                "locality": "BIRMINGHAM",
                "region": "UKG31",
                "postalCode": "B152TT",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Susanna Ting",
                "email": "s.y.ting@bham.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.birmingham.ac.uk/index.aspx",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "09",
                        "description": "Education"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-37276",
            "name": "Medidata Solutions International Limited",
            "identifier": {
                "legalName": "Medidata Solutions International Limited"
            },
            "address": {
                "streetAddress": "12 Hammersmith Grove, 9th Floor",
                "locality": "London",
                "region": "UKI",
                "postalCode": "W6 7AP",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-36673",
            "name": "The University of Birmingham",
            "identifier": {
                "legalName": "The University of Birmingham"
            },
            "address": {
                "locality": "Birmingham",
                "postalCode": "B152TT",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-31013",
        "name": "UNIVERSITY OF BIRMINGHAM"
    },
    "contracts": [
        {
            "id": "030689-2021-SC9830/21-1",
            "awardID": "030689-2021-SC9830/21-1",
            "title": "PARIS Trial Clinical Trials EDC system: A phase 2 study of PD-1 inhibition in Rheumatoid Arthritis, Ulcerative Colitis and Sjogrens syndrome",
            "status": "active",
            "value": {
                "amount": 500000,
                "currency": "GBP"
            },
            "dateSigned": "2021-12-09T00:00:00Z"
        }
    ],
    "language": "en"
}